Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Bullboard (TSXV:ARCH)

View:
Post by Riverfolkon Apr 08, 2023 9:17pm

LSALT / Metablok Background

Inflammation Based Disease Inflammation is a localized physical condition that involves the activation of the immune system in response to infection, tissue injury, or autoimmunity. Inflammation is ...more  
Post by Riverfolkon Apr 08, 2023 9:10pm

dipeptidase-1 contribute to contrast-induced AKI

Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury https://www.ncbi.nlm.nih.gov
Post by Riverfolkon Apr 08, 2023 9:04pm

Dipeptidase-1 governs renal inflammation

Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury https://www.science.org
Post by Riverfolkon Apr 08, 2023 9:00pm

Dipeptidase-1 - Adhesion Receptor for Neutrophil Recruitor

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver https://www.cell.com
Post by Riverfolkon Apr 08, 2023 8:49pm

About DPEP-1 and Organ Inflammation

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In ...more  
Post by Riverfolkon Apr 08, 2023 8:44pm

(CIHR) Project Grant worth $1,109,250

To further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD). The CIHR grant entitled “A Multifaceted Function for Dipeptidase-1 in Kidney Injury” was ...more  
Post by Riverfolkon Apr 08, 2023 8:41pm

ARCH $4,000,000 funding from the National Research Council

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs ...more  
Post by Riverfolkon Apr 08, 2023 8:34pm

Active Pharma Executive - ARCH Strategic Advisor

Mr. Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as head of Finance and Human Resources for the Arabian Gulf countries and has since held finance and ...more  
Post by Riverfolkon Apr 08, 2023 8:26pm

Treating Liver Inflammation

Treating Liver Inflammation
Post by Riverfolkon Apr 08, 2023 7:16am

Treating Kidney Inflammation

Treating Kidney Inflammation
Post by Riverfolkon Apr 08, 2023 7:15am

Treating Lung Inflammation

Treating Lung Inflammation
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities